Insider trades

N. Anthony Coles, Director of Regeneron Pharmaceuticals REGN, has filed 0 purchases and 26 sales on the open market. The latest trade was on 01/02.

N. Anthony Coles

Director
First filing
23/01/05
Trades
85 trades
Buys / sales
0 / 26
12-month net buying
No record
Last trade
01/02

Trading activity

Transactions

Trade type
Open-market sale10b5-1 plan24/07/0124/07/0325,000 sh$41.18$1,029,500−49.1%
Open-market sale10b5-1 plan24/06/0324/06/0550,000 sh$40.61$2,030,500−76.2%
Open-market sale10b5-1 plan24/05/1024/05/1450,000 sh$42.10$2,105,000−76.2%
Open-market sale10b5-1 plan24/04/0124/04/0350,000 sh$42.33$2,116,500−76.2%
Open-market sale10b5-1 plan24/03/0424/03/0650,000 sh$41.01$2,050,500−76.2%
Open-market sale10b5-1 plan24/02/2924/03/0450,000 sh$41.16$2,058,000−76.2%
Open-market sale24/02/0724/02/082,506 sh$41.54$104,099.24−13.8%
Open-market sale10b5-1 plan24/01/0224/01/0450,000 sh$42.24$2,112,000−94.9%
Open-market sale23/11/1423/11/1622,824 sh$25.13$573,567.12−89.4%
Open-market sale23/11/07–23/11/0823/11/0927,176 sh2 trades$25.02avg.$679,957.52−91.0%
Open-market sale23/11/02–23/11/0323/11/06100,000 sh2 trades$25.34avg.$2,533,736.24−97.4%
Open-market sale23/09/0723/09/0850,000 sh$24.07$1,203,500−94.9%
Open-market sale10b5-1 plan23/07/1123/07/1350,000 sh$30.03$1,501,500−94.9%
Open-market sale10b5-1 plan23/06/0123/06/0550,000 sh$32.60$1,630,000−94.9%
Open-market sale10b5-1 plan23/05/0423/05/0850,000 sh3 trades$31.47avg.$1,573,323.8−94.9%
Open-market sale10b5-1 plan23/04/1123/04/1350,000 sh$25.06$1,253,000−94.9%
Open-market sale23/03/02–23/03/0323/03/0650,000 sh2 trades$27.11avg.$1,355,740−94.9%
Open-market sale23/02/0723/02/0850,000 sh2 trades$33.12avg.$1,656,209.26−94.9%
Open-market sale23/01/0523/01/0650,000 sh2 trades$29.94avg.$1,496,900−94.9%